VC: Hyperion lands $40M in second round



Hyperion lands $40M in second round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Hyperion Therapeutics
South San Francisco

$40M
Second

Sofinnova Ventures

The funding will allow Hyperion to complete the licensing deal with Medicis Pharmaceutical Corporation, build out its management team, advance clinical trials and begin U.S. promotion of the two compounds for the treatment of UCD.

Agendia
Amsterdam

$34M
Fourth

ING, Van Herk Biotech, Gilde Healthcare Partners and Global Life Science Ventures

The company developed the MammaPrint, a prognostic DNA microarray-based in vitro diagnostic test that measures the activity of 70 genes to assess the risk of breast cancer recurrence.

Presidio Pharmaceuticals
San Francisco

$26M
Second

Panorama Capital

Presidio Pharmaceuticals is focused on developing therapies for chronic viral infections.

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.